Montecito Bank & Trust’s CytomX Therapeutics CTMX Stock Holding History

Montecito Bank & Trust’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-21,561	Closed	-$493K	–	204
2018 Q2	$493K	Sell	21,561 -2,301	-10%	-$58.8K	0.16%	115
2018 Q1	$679K	Sell	23,862 -1,740	-7%	-$49.7K	0.22%	82
2017 Q4	$540K	Sell	25,602 -3,000	-10%	-$62.2K	0.18%	101
2017 Q3	$520K	Hold	28,602	–	–	0.18%	101
2017 Q2	$443K	Sell	28,602 -117,942	-80%	-$1.78M	0.16%	111
2017 Q1	$2.53M	Hold	146,544	–	–	0.92%	22
2016 Q4	$1.61M	Hold	146,544	–	–	0.56%	41
2016 Q3	$2.3M	Hold	146,544	–	–	0.94%	25
2016 Q2	$1.5M	Buy	+146,544	New	+$1.67M	0.63%	35

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Montecito Bank & Trust's CTMX Position: Q3 2018 in Review

Montecito Bank & Trust sold out of CytomX Therapeutics (CTMX) in Q3 2018, closing a stake of 21,561 shares — an estimated $493K sold.

Montecito Bank & Trust first reported a position in CTMX in Q2 2016 and held it in 9 quarters. The position peaked at $2.53M in Q1 2017. 122 funds tracked by Wall St. Rank hold CTMX as of Q3 2018.

Montecito Bank & Trust reported no remaining CytomX Therapeutics position as of Q3 2018 after selling out during the quarter.
Montecito Bank & Trust sold 21,561 CytomX Therapeutics shares in Q3 2018, an estimated $493K.
Montecito Bank & Trust first reported a position in CytomX Therapeutics in Q2 2016 and held it in 9 quarters.
Montecito Bank & Trust's CytomX Therapeutics position peaked at $2.53M in Q1 2017.
122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2018.

Based on Montecito Bank & Trust's 13F filing for Q3 2018, filed 11 Oct 2018.